Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

In a court filing earlier this month, the FDA agreed to reconsider a decision last month to bar drug compounders from selling their versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...

The drugmaker has received approval from the Hong Kong government to sell its tirzepatide injections — branded as Mounjaro — ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...